CAR-T therapies in solid tumors: opportunities and challenges
G Guzman, MR Reed, K Bielamowicz, B Koss… - Current oncology …, 2023 - Springer
G Guzman, MR Reed, K Bielamowicz, B Koss, A Rodriguez
Current oncology reports, 2023•SpringerAbstract Purpose of Review This review will discuss the challenges facing chimeric antigen
receptor (CAR)-T cell application for solid tumors and opportunities to overcome these
obstacles. In addition, this review will examine therapies that are in development for
pediatric solid tumors. Recent Findings The similar success of CAR-T cell treatment for
hematological malignancies has not been observed in solid tumors because of the hostile
tumor microenvironment and tumor heterogeneity. Most strategies developed to combat …
receptor (CAR)-T cell application for solid tumors and opportunities to overcome these
obstacles. In addition, this review will examine therapies that are in development for
pediatric solid tumors. Recent Findings The similar success of CAR-T cell treatment for
hematological malignancies has not been observed in solid tumors because of the hostile
tumor microenvironment and tumor heterogeneity. Most strategies developed to combat …
Purpose of Review
This review will discuss the challenges facing chimeric antigen receptor (CAR)-T cell application for solid tumors and opportunities to overcome these obstacles. In addition, this review will examine therapies that are in development for pediatric solid tumors.
Recent Findings
The similar success of CAR-T cell treatment for hematological malignancies has not been observed in solid tumors because of the hostile tumor microenvironment and tumor heterogeneity. Most strategies developed to combat these limitations emphasize combinatorial techniques that still require further testing. Preliminary results of multiple clinical trials, including GD2- and HER2-CAR-T cells, are encouraging but must be reproduced and validated on a larger scale.
Summary
CAR-T cell application in solid tumors remains challenging, and most research is in development. Several clinical trials are ongoing for pediatric solid tumors. Early results are promising but demonstrate the need for CAR-T cell modification to prevent tumor recurrence.
Springer
